



### **BACKGROUND INFORMATION**

To obtain credit, read the material and complete the Posttest and Registration Form on pages 24–26.

#### **CME Objectives**

After completing this educational activity, you should be able to:

- Discuss issues related to sedation versus sleep versus efficacy in the use of atypical antipsychotics
- Review the evidence on metabolic changes associated with the use of atypical antipsychotics
- Describe a strategy for managing drug-induced movement disorders, including extrapyramidal symptoms and tardive dyskinesia
- Manage anticholinergic side effects in antipsychotic-treated patients

#### **Statement of Need and Purpose**

Atypical antipsychotics are increasingly being used for special populations, such as children and the elderly, and for new indications, including severe anxiety and affective disorders. This educational activity is designed to meet the needs of primary care physicians who have requested information about the use of atypical antipsychotics in their practice. There are no prerequisites for participating in this activity.

#### **Accreditation Statement**

Physicians Postgraduate Press, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

#### **Credit Designation**

Physicians Postgraduate Press, Inc. designates this educational activity for up to 3 Category 1 credits toward the AMA Physician's Recognition Award. Each participant should claim only those credits that he/she actually spent in the educational activity.

#### **Date of Original Release/Review**

This Supplement was published in April 2004 and is eligible for CME credit through April 30, 2006.

The latest review of this material was October 2003.

#### **Faculty**

**Chair:** Joseph A. Lieberman, III, M.D., M.P.H. **Faculty:** Del D. Miller, Pharm.D., M.D.; Delbert G. Robinson, M.D.; Bruce L. Saltz, M.D.; and Margaret G. Woerner, Ph.D.

**Faculty Disclosure** appears on the inside back cover.

#### **Disclosure of Off-Label Usage**

In this Supplement, faculty may be presenting investigational information about pharmaceutical agents that is outside U.S. Food and Drug Administration–approved labeling. This information is intended solely as continuing medical education and is not intended to promote off-label use of any of these medications. Please consult the paragraph titled “Disclosure of Off-Label Usage” at the end of each article for a complete listing of off-label or investigational uses. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.

### **REVIEW PROCESS**

This activity has undergone a 3-tier review process: (1) the entire faculty discussed the content at a peer-review planning session; (2) the chair reviewed the activity for accuracy and fair balance; and (3) a member of the External CME Advisory Board reviewed the activity to determine whether the material meets the stated objectives and the posttest accurately reflects the content.

### **ACKNOWLEDGMENT**

The material in this Supplement was presented at the planning roundtable “Using Atypical Antipsychotics in Primary Care,” which was held June 2–4, 2002, in Washington, D.C. This Supplement was independently developed by the CME Institute of Physicians Postgraduate Press, Inc. pursuant to an unrestricted educational grant from Janssen Pharmaceutica, L.P. Editorial assistance was provided by Physicians Postgraduate Press, Inc. The opinions expressed herein are those of the authors and do not necessarily reflect the views of the CME provider and publisher or the commercial supporter.